p63 anticorps

N° du produit ABIN4949376

Cet anticorps Lapin Polyclonal détecte spécifiquement p63 dans IF, IHC (p) et FACS. Il présente une réactivité envers Humain.

Aperçu rapide pour p63 anticorps (ABIN4949376)

Antigène: p63 (TP63) (Tumor Protein P63 (TP63))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp p63 est non-conjugé

Application: Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Flow Cytometry (FACS)

Détail du produit anti-p63 anticorps

Purification: Protein A affinity chromatography

Immunogène: Recombinant partial human p53 protein was used as the immunogen for this p63 antibody.

Isotype: IgG

Information d'application

Indications d'application: The optimal dilution of the p63 antibody for each application should be determined by the researcher.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 1-2 μg/mL,Immunohistochemistry (FFPE): 1-2 μg/mL for 30 minutes at RT

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: Store the p63 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Détails sur p63

Antigène: p63 (TP63) (Tumor Protein P63 (TP63))

Autre désignation: p63 / Tumor protein 63

Sujet: P63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands, however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90 % . Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80 %. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.